The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-12. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
In 1979, the toppling of US-allied governments in Iran and Nicaragua and the outbreak of the Soviet–Afghan War again raised tensions. In 1985, Mikhail Gorbachev became leader of the USSR and expanded political freedoms, which contributed to the revolutions of 1989 in the Eastern Bloc and the collapse of the USSR in 1991, ending the Cold War.
In 2010, the US government began cracking down on pharmacists and doctors who were overprescribing opioid painkillers. An unintended consequence of this was that those addicted to prescription opiates turned to heroin, a significantly more potent but cheaper opioid, as a substitute. A 2017 survey in Utah of heroin users found about 80 percent started with prescription drugs. In 2010, the Controlled Substances Act was amended with the Secure and Responsible Drug Disposal Act, which allows pharmacies to accept controlled substances from households or long-term care facilities in their drug disposal programs or "take-back" programs. In 2011, the federal government released a white paper describing the administration's plan to deal with the crisis. Its concerns have been echoed by numerous medical and government advisory groups around the world. In July 2016, President Barack Obama signed into law the Comprehensive Addiction and Recovery Act, which expands opioid addiction treatment with buprenorphine and authorizes millions of dollars in funding for opioid research and treatment. In 2011, the Obama administration began to deal with the crisis, and in 2016, President Barack Obama authorized millions of dollars in funding for opioid research and treatment, followed by CDC director Thomas Frieden stating that "America is awash in opioids; urgent action is critical." Soon after, many state governors declared a "state of emergency" to combat the opioid epidemic in their own states, and undertook major efforts to stop it.
=== In cancer === Periostin over-expression was reported in several types of cancer, most frequently in the environment of tumor cells. Recent evidence shows that periostin is a component of the extracellular matrix expressed by fibroblasts in normal tissues and stroma of primary tumor. The metastatic colony formation requires the induction of periostin in the foreign stroma by the infiltrating cancer cells. Periostin production is upregulated in lung fibroblasts by either TGF-β2 or TGF-β3, the latter being secreted by infiltrating cancer stem cells (in MMTV-PyMT mouse breast cancer model) Periostin has been shown to be highly upregulated in glioblastomas (grade IV gliomas) compared to the normal brain. In gliomas, periostin expression levels correlate directly with tumor grade and recurrence, and inversely with survival. It has been shown that glioma stem cells in glioblastomas secrete periostin, which recruits M2 tumor-associated macrophages from peripheral blood to the tumor environment via αvβ3 integrin signaling. These M2 TAMs differentiate from monocytes once they enter the tumor tissue. Through this recruitment mechanism, periostin supports tumor progression, as M2 tumor-associated macrophages are tumor-supportive and immunosuppressive. In this environment, periostin functions as a chemoattractant, promoting both migration and invasion of macrophages and monocytes into glioblastomas in a dose-dependent manner. Clinically, periostin-associated gene signatures, which are predominated by secreted and matrix proteins, correspond to patient prognosis and malignancy.
Articulated laticifers, i.e., composed of a series of cells joined together, or Non-articulated laticifers, consisting of one long coenocytic cell. Non-articulated laticifers begin their growth from the meristematic tissue of the embryo, termed the laticifer initial, and can exhibit continual growth throughout the lifetime of the plant. Laticifer tubes have irregularly edged walls and a larger inner diameter than the surrounding parenchyma cells. In the development of the cell, elongation occurs via karyokinesis and no cell plate develops resulting in coenocytic cells which extend throughout the plant. These cells can reach up to tens of centimeters long and can be branched or unbranched. They are thought to have a role in wound healing and as defense against herbivory, as well as pathogen defense, and are often used for taxonomy. Laticifers were first described by Anton de Bary in 1877. Laticifers are highly specialized cells which can produce a wide variety of proteins. These proteins include enzymes functioning as proteinases and chitinases which help defend the producing plant against insects and other herbivores. In one study it was found that the presence and concentration of some proteins can differ greatly within the genus Croton relative to three species studied.
== List of major publications in English == Vladimir Kh. Khavinson. Peptides and Ageing. // Neuroendocrinology Letters. — Vol. 23, Suppl. 3, Special Issue. — 2002. — 144 p. Khavinson, Malinin. Gerontological Aspects of Genome Peptide Regulation. // Basel (Switzerland): Karger AG. — 2005. — 104 p. Khavinson. Peptidergic regulation of ageing. // SPb.: Humanistica. — 2009. — 48 p. Khavinson, Morozov, Anisimov. Experimental Studies of the Pineal Gland Preparation Epithalamin. // The Pineal Gland and Cancer. — Bartsch C., Bartsch H., Blask D.E., Cardinali D.P., Hrushesky W.J.M., Mecke D. (Eds.) — Springer-Verlag, Berlin, Heidelberg. — 2001. — P. 294–306. Vladimir N. Anisimov, Vladimir Kh. Khavinson. Small Peptide-associated Modulation of Aging and Longevity. // Modulating Aging and Longevity. — Kluwer Academic Publishers (Printed in the United Kingdom) — Suresh I.S. Rattan (ed.). — 2003. — P. 279–301. Vladimir N. Anisimov, Vladimir Kh. Khavinson. Pineal Peptides as Modulators of Aging. // Aging Interventions and Therapies. — World Scientific. — Suresh I.S. Rattan (ed.). — 2005. — P. 127–146. Khavinson, Mikhailova. Health and Aging in Russia. // Global Health and Global Aging. / (ed. by Mary Robinson et al.); foreword by Robert Butler. — 1st ed. — 2007. — P. 226–237. Khavinson, Neroev, Trofimova, Osokina. Unique method for restoration of retinal functions in case of different diseases. // SPb. — 2011. — 32 p.
Sources: en.wikipedia.org
The society – which only admitted men at the time – initially mistook Benett for a man due to her reputation as a scientist and her unusual first name, addressing her diploma of admission to "Dominum" (Master) Benett. 1840: Scottish fossil collector and illustrator Lady Eliza Maria Gordon-Cumming invited geologists Louis Agassiz, William Buckland and Roderick Murchison to examine her collection of fish fossils. Agassiz confirmed several of Gordon-Cumming's discoveries as new species. 1843: During a nine-month period in 1842–43, English mathematician Ada Lovelace translated Luigi Menabrea's article on Charles Babbage's newest proposed machine, the Analytical Engine. With the article, she appended a set of notes. Her notes were labelled alphabetically from A to G. In note G, she describes an algorithm for the Analytical Engine to compute Bernoulli numbers. It is considered the first published algorithm ever specifically tailored for implementation on a computer, and Ada Lovelace has often been cited as the first computer programmer for this reason. The engine was never completed, so her program was never tested. 1843: British botanist and pioneering photographer Anna Atkins self-published her book Photographs of British Algae, illustrating the work with cyanotypes. Her book was the first book on any subject to be illustrated by photographs. 1846: British zoologist Anna Thynne built the first stable, self-sustaining marine aquarium.
Evaporated milk is sometimes used in its concentrated form in tea or coffee, or as a topping for desserts. Reconstituted evaporated milk, roughly equivalent to normal milk, is mixed one part by volume of evaporated milk with 1 1/4 parts of water.
== Regulatory status == D-Ribose-L-cysteine is regulated in the United States as a dietary supplement ingredient, not as a pharmaceutical drug. Products containing D-ribose-L-cysteine are subject to dietary supplement regulations under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which prohibit claims that a product can diagnose, treat, cure, or prevent disease. No pharmaceutical drug approvals or therapeutic indications have been granted for D-ribose-L-cysteine by the U.S. Food and Drug Administration.
== Research == Lebrikizumab is under investigation as an immunosuppressive medication for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. It was created by Tanox under the code name TNX-650, and a phase I clinical trial for refractory Hodgkin's lymphoma had been performed when Genentech acquired Tanox in 2007. It has successfully completed a phase II clinical trial for the treatment of asthma.
Sources: en.wikipedia.org
Dyson and Hugh Montgomery discovered an intriguing connection between quantum physics and Montgomery's pair correlation conjecture about the zeros of the zeta function. The primes 2, 3, 5, 7, 11, 13, 17, 19,... are described by the Riemann zeta function, and Dyson had previously developed a description of quantum physics based on m by m arrays of totally random numbers. Montgomery and Dyson discovered that the eigenvalues of these matrices are spaced apart in exactly the same manner as Montgomery conjectured for the nontrivial zeros of the zeta function. Andrew Odlyzko has verified the conjecture on a computer, using his Odlyzko–Schönhage algorithm to calculate many zeros. There are in nature one, two, and three-dimensional quasicrystals. Mathematicians define a quasicrystal as a set of discrete points whose Fourier transform is also a set of discrete points. Odlyzko has done extensive computations of the Fourier transform of the nontrivial zeros of the zeta function, and they seem to form a one-dimensional quasicrystal. This would in fact follow from the Riemann hypothesis.
== Epidemiology == Diabetic ketoacidosis occurs in 4.6–8.0 per 1000 people with diabetes annually. Rates among those with type 1 diabetes are higher with about 4% in the United Kingdom developing DKA a year while in Malaysia the condition affects about 25% a year. In the United States, 135,000 hospital admissions occur annually as a result of DKA, at an estimated cost of $2.4 billion or a quarter to half the total cost of caring for people with type 1 diabetes. There has been a documented increasing trend in hospital admissions. The risk is increased in those with an ongoing risk factor, such as an eating disorder, and those who cannot afford insulin. About 30% of children with type 1 diabetes receive their diagnosis after an episode of DKA. Lower socio‐economic status and higher area‐level deprivation are associated with an increased risk of diabetic ketoacidosis in people with diabetes mellitus type 1. Previously considered universally fatal, the risk of death with adequate and timely treatment is between <1% and 5%. However, despite low acute mortality rates, an episode of DKA remains a significant predictor of death over the subsequent 12 months. Up to 1% of children with DKA develop a complication known as cerebral edema. Rates of cerebral edema in US children with DKA have risen from 0.4% in 2002 to 0.7% in 2012. Between 2 and 5 out of 10 children who develop brain swelling will die as a result.
=== Contestants === 1st - Manny Martinez, Bakery Owner from San Antonio, Texas 2/3/4th - Aaron Davis, Pastry Lead from Surprise, Arizona. 2/3/4th - Joel Gonzalez, Executive Pastry Chef from Scottsdale, Arizona 2/3/4th - Hollie Rivera, Assistant Pastry Chef from Winnipeg, Manitoba 5th - Lillian Chng, Home Bakery Owner from San Diego, California 6th - Thierry Aujard, Executive Pastry Chef from Norristown, Pennsylvania 7th - Megan Aucone, Pastry Chef and Cake Artist from Sayreville, New Jersey 8th - JL Hinojosa, Pastry Chef de Partie from Austin, Texas 9th - Carly Robertson, Bakery Owner from Lehi, Utah 10th - Samantha Santiago Torres, Executive Pastry Chef from Chicago, Illinois
10 mm (0.4 in) – it has well-defined gill arches and has a thin ventral finfold 21 mm (0.8 in) – dorsal and pelvic fin buds appear 33 mm (1.3 in) – embryo has protruding eyes and well-developed gill filaments 43 mm (1.7 in) – it has lost its translucency and develops slits in the egg case, allowing fluid exchange from surrounding seawater and the interior 58 mm (2.3 in) – the finfold starts to decay 66 mm (2.6 in) – the finfold and gill filaments are reduced or absent 74 mm (2.9 in) – external appearance is complete but yolk sac is still being absorbed 100–110 mm (3.9–4.3 in) – hatching
=== Proteasomal deubiquitinases === Ubiquitin chains conjugated to a protein targeted for proteasomal degradation are normally removed by any one of the three proteasome-associated deubiquitylating enzymes (DUBs), which are Rpn11, Ubp6/USP14 and UCH37. Rpn11 is the essential DUB responsible for the en block removal of the ubiquitin signal from the substrate, while Ubp6/USP14 and UCH37 have been proposed to edit the ubiquitin code. Ubp6 knockouts in Saccharomyces cerevisiae are viable, and there is no homolog of UCH37 in budding yeast, though they exist in Schizosaccharomyces pombe and higher eukaryotes. This process recycles ubiquitin and is essential to maintain the ubiquitin reservoir in cells.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.